长期辅助内分泌治疗与非转移性乳腺癌女性心血管疾病风险的系统综述
该系统综述与荟萃分析纳入26项随机对照试验和观察性研究,评估他莫昔芬或芳香化酶抑制剂对非转移性乳腺癌女性7种特定心血管结局的风险。结果提示他莫昔芬使用者静脉血栓栓塞风险增加,芳香化酶抑制剂使用者心肌梗死和心绞痛风险可能高于他莫昔芬使用者,其他心血管结局证据不一致。
要点
- 他莫昔芬使用者静脉血栓栓塞风险高于非使用者及芳香化酶抑制剂使用者。
- 芳香化酶抑制剂使用者心肌梗死和心绞痛风险可能高于他莫昔芬使用者。
- 选择内分泌治疗时除考虑乳腺癌复发疗效外,应个体化评估静脉或动脉血管疾病风险。
核心结论
- 他莫昔芬使用者静脉血栓栓塞风险增加,芳香化酶抑制剂使用者心肌梗死和心绞痛风险可能高于他莫昔芬使用者,其他心血管结局证据不一致。
研究设计与样本
- 系统综述与荟萃分析,纳入26项随机对照试验和观察性研究,检索Medline和Embase至2018年6月。
主要发现
- 他莫昔芬使用者静脉血栓栓塞风险高于非使用者及芳香化酶抑制剂使用者。
- 芳香化酶抑制剂使用者心肌梗死和心绞痛风险可能高于他莫昔芬使用者,部分可能由他莫昔芬对这些结局的保护效应驱动。
- 其他心血管疾病结局数据有限且证据不一致。
关键数值与推荐
- 纳入研究需探讨他莫昔芬或芳香化酶抑制剂相关的特定心血管疾病结局风险,或比较两种治疗。
- 采用Cochrane协作组工具评估随机对照试验偏倚风险,并改编该工具评估观察性研究偏倚风险。
临床怎么用
- 芳香化酶抑制剂或他莫昔芬的选择主要基于对乳腺癌复发的疗效,但个体患者静脉或动脉血管疾病风险应作为重要次要考虑。
局限性
- 其他心血管疾病结局数据有限且证据不一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the effect of endocrine therapies on a wide range of specific clinical cardiovascular disease outcomes in women with a history of non-metastatic breast cancer. DESIGN: Systematic review and meta-analysis of randomised controlled trials and observational studies. DATA SOURCES: Medline and Embase up until June 2018. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Studies were included if they investigated the risk of a specific cardiovascular disease outcome associated with use of either tamoxifen or an aromatase inhibitor, or compared the two treatments, in women with a history of non-metastatic breast cancer. APPRAISAL AND DATA EXTRACTION: Relevant studies were originally identified and results extracted by one researcher, with a full replication of the study identification process by a combination of two other researchers. The Cochrane Collaboration's tool for assessing risk of bias was used to assess risk of bias in randomised controlled trials, and this tool was adapted to assess risk of bias in observational studies. RESULTS: 26 studies were identified, with results for seven specific cardiovascular disease outcomes (venous thromboembolism, myocardial infarction, stroke, angina, heart failure, arrhythmia, and peripheral vascular disease). Results suggested an increased risk of venous thromboembolism in tamoxifen users compared with both non-users and aromatase inhibitor users. Results were also consistent with a higher risk of the vascular diseases myocardial infarction and angina in aromatase inhibitor users compared with tamoxifen users, but there was also a suggestion that this may be partly driven by a protective effect of tamoxifen on these outcomes. Data were limited, and evidence was generally inconsistent for all other cardiovascular disease outcomes. CONCLUSION: This review has collated substantial randomised controlled trial and observational evidence on the effect of endocrine therapies on several specific cardiovascular disease outcomes including venous thromboembolism and myocardial infarction, progressing knowledge. Although the choice of aromatase inhibitor or tamoxifen will primarily be based on the effectiveness against the recurrence of breast cancer, this review shows that the individual patient's risk of venous or arterial vascular disease should be an important secondary consideration. SYSTEMATIC REVIEW REGISTRATION: Prospero CRD42017065944.
引用
- Matthews A, Stanway S, Farmer RE, et al. Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review. BMJ. 2018. PMID: 30297439. doi:10.1136/bmj.k3845
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。